Insmed Incorporated (NASDAQ:INSM) Insider Orlov S. Nicole Schaeffer Sells 1,642 Shares

Insmed Incorporated (NASDAQ:INSM - Get Free Report) insider Orlov S. Nicole Schaeffer sold 1,642 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $71.50, for a total value of $117,403.00. Following the completion of the sale, the insider now directly owns 118,579 shares of the company's stock, valued at $8,478,398.50. The trade was a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Insmed Price Performance

NASDAQ:INSM traded up $0.83 during trading hours on Friday, hitting $73.57. The stock had a trading volume of 704,483 shares, compared to its average volume of 2,071,497. The company has a 50 day simple moving average of $69.25 and a two-hundred day simple moving average of $73.03. The firm has a market capitalization of $13.40 billion, a price-to-earnings ratio of -13.17 and a beta of 0.80. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a one year low of $55.74 and a one year high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. During the same quarter last year, the business posted ($1.06) EPS. The company's quarterly revenue was up 22.9% on a year-over-year basis. Research analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Institutional Trading of Insmed

Large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Insmed by 0.3% in the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock valued at $1,393,675,000 after purchasing an additional 49,149 shares in the last quarter. Darwin Global Management Ltd. increased its holdings in shares of Insmed by 23.5% in the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock worth $894,796,000 after buying an additional 2,463,261 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Insmed by 1.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company's stock worth $985,938,000 after buying an additional 219,131 shares during the last quarter. Capital International Investors lifted its holdings in shares of Insmed by 9.1% during the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock worth $491,357,000 after acquiring an additional 593,206 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Insmed by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock worth $282,243,000 after acquiring an additional 273,759 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on INSM shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Insmed in a research note on Wednesday, February 19th. Jefferies Financial Group began coverage on Insmed in a research report on Tuesday, May 13th. They set a "buy" rating and a $105.00 price target for the company. Guggenheim reissued a "buy" rating and issued a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. Stifel Nicolaus decreased their target price on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Friday, February 21st. Finally, Truist Financial lifted their target price on Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Insmed presently has an average rating of "Moderate Buy" and a consensus price target of $96.73.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.